Futibatinib is a new type of targeted drug developed in recent years, specifically for the treatment of bile duct diseases. Its precise targeting ability and good tolerability make it the preferred treatment for many patients. So, what are the side effects of futibatinib?
What are the side effects of futibatinib?
As a new type of targeted drug, futibatinib, like other therapeutic drugs, may also cause certain adverse reactions. The following is an introduction to the possible side effects of futibatinib:
Retinal pigment epithelial detachment (RPED)
Futibatinib can cause RPED, which may cause symptoms such as blurred vision and visual field defects. Among patients treated with futibatinib, a certain proportion of patients developed RPED.
Hyperphosphatemia and soft tissue mineralization
Futibatinib can cause hyperphosphatemia, leading to adverse reactions such as soft tissue mineralization, calcification, non-uremic calcification reaction and vascular calcification. Increased phosphate levels are one of the pharmacodynamic effects of futibatinib.
Futibatinib has shown good efficacy in the treatment of bile duct diseases, but it may also cause a series of side effects. Patients should closely monitor their physical condition during use. If they feel unwell, they should seek medical attention in time and inform their doctors that they are using futibatinib. The doctor will adjust the treatment plan according to the patient's specific situation to minimize the impact of side effects.
Futibatinib side effect relief measures
For the side effects of futibatinib, the following relief measures can be taken:
Retinal pigment epithelial detachment (RPED)
Perform a comprehensive ophthalmological examination before the start of treatment and monitor regularly during treatment, especially every 2 months for the first 6 months and every 3 months thereafter. For the onset of visual symptoms, refer for ophthalmological evaluation immediately, and stop or reduce the dose of futibatinib as recommended by the doctor.
Hyperphosphatemia and soft tissue mineralization
Monitor phosphate levels regularly, and start a low-phosphate diet and phosphate-lowering therapy when the serum phosphate level is ≥5.5mg/dL. For patients with serum phosphate levels >7mg/dL, phosphate-lowering therapy should be initiated or intensified, and the dose of Futibatinib should be reduced, stopped, or permanently discontinued depending on the duration and severity of hyperphosphatemia.
The side effects of Futibatinib are inevitable, and the impact on patients' lives can be minimized through timely monitoring and effective response measures. When using Futibatinib, patients should closely monitor their physical condition, communicate with their doctors in a timely manner, and jointly develop a personalized treatment plan.
